.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Argus Health
Dow
McKesson
UBS
Baxter
Moodys
Daiichi Sankyo
Johnson and Johnson

Generated: November 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,608,029

« Back to Dashboard

Claims for Patent: 6,608,029

Title: Methods for regulating gastrointestinal motility
Abstract:Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.
Inventor(s): Kolterman; Orville G. (Poway, CA), Young; Andrew A. (Alpine, CA), Rink; Timothy J. (La Jolla, CA), Keating Brown; Kathleen Ann (Wake Forest, NC)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:09/576,062
Patent Claims: 1. A method of reducing gastric motility or delaying gastric emptying in a mammal comprising administering to said mammal a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is an amylin agonist analogue having the following amino acid sequence: .sup.1 A.sup.1 -X-Asn-Thr-.sup.5 Ala-Thr-Y-Ala-Thr-.sup.10 Gln-Arg-Leu-B.sub.1 -Asn-.sup.15 Phe-Leu-C.sub.1 -D.sub.1 -E.sub.1 -.sup.20 F.sub.1 -G.sub.1 -Asn-H.sub.1 -Gly-.sup.25 Pro-I.sub.1 -Leu-Pro-J.sub.1 -.sup.30 Thr-K.sub.1 -Val-Gly-Ser-.sup.35 Asn-Thr-Tyr-Z

wherein A.sub.1 is Lys, Ala, Ser or hydrogen; B.sub.1 is Ala, Ser or Thr; C.sub.1 is Val, Leu or Ile; D.sup.1 is His or Arg; E.sub.1 is Ser or Thr; F.sub.1 is Ser, Thr, Gln or Asn; G.sup.1 is Asn, Gln or His; H.sup.1 is Phe, Leu or Tyr; I.sub.1 is Ile, Val, Ala or Leu; J.sub.1 is Ser, Pro or Thr; K.sub.1 is Asn, Asp or Gln; X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy, and provided that when (a) A.sub.1 is Lys, B.sub.1 is Ala, C.sub.1 is Val, D.sub.1 is Arg, E.sub.1 is Ser, F.sub.1 is Ser, G.sub.1 is Asn, H1 is Leu, I.sub.1 is Val, J.sub.1 is Pro, and K.sub.1 is Asn; or (b) A.sub.1 is Lys, B.sub.1 is Ala, C.sub.1 is Val, D.sub.1 is His, E.sub.1 is Ser, F.sub.1 is Asn, G.sub.1 is Asn, H.sub.1 is Leu, I.sub.1 is Val, J.sub.1 is Ser, and K.sub.1 is Asn; then one or more of A.sub.1 to K.sub.1 is a D-amino acid and Z is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and wherein said agonist exhibits a nucleus accumbens receptor binding activity of 5 nM or less.

2. A method according to claim 1 wherein X and Y comprise Cys residues linked by a disulfide bond.

3. A method according to claim 2 wherein Z is amino.

4. The method of claim 1 wherein said amylin agonist is administered parenterally.

5. The method of claim 1 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 1 nM or less.

6. The method of claim 1 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 50 pM or less.

7. A method of reducing gastric motility or delaying gastric emptying in a mammal comprising administering to said mammal a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is an amylin agonist analogue having the following amino acid sequence: .sup.1 A.sub.1 -X-Asn-Thr-.sup.5 Ala-Thr-Y-Ala-Thr-.sup.10 Gln-Arg-Leu-B.sub.1 -Asn-.sup.15 Phe-Leu-C.sub.1 -D.sub.1 -E.sub.1 -.sup.20 F.sub.1 -G.sub.1 -Asn-H.sub.1 -Gly-.sup.25 Pro-I.sub.1 -Leu-J.sub.1 -Pro-.sup.30 Thr-K.sub.1 -Val-Gly-Ser-.sup.35 Asn-Thr-Tyr-Z

wherein A.sub.1 is Lys, Ala, Ser or hydrogen; B.sub.1 is Ala, Ser or Thr; C.sub.1 is Val, Leu or Ile; D.sub.1 is His or Arg; E.sub.1 is Ser or Thr; F.sub.1 is Ser, Thr, Gln or Asn; G.sub.1 is Asn, Gln or His; H.sub.1 is Phe, Leu or Tyr; I.sub.1 is Ile, Val, Ala or Leu; J.sub.1 is Ser, Pro, Leu, Ile or Thr; K.sub.1 K is Asn, Asp or Gln; X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when (a) A.sub.1 is Lys, B.sub.1 is Ala, C.sub.1 is Val, D.sub.1 is Arg, E.sub.1 is Ser, F.sub.1 is Ser, G.sub.1 is Asn, H.sub.1 is Leu, I.sub.1 is Val, J.sub.1 is Pro and K.sub.1 is Asn; or (b) A.sub.1 is Lys, B.sub.1 is Ala, C.sub.1 is Val, D.sub.1 is His, E.sub.1 is Ser, F.sub.1 is Asn, G.sub.1 is Asn, H.sub.1 is Leu, I.sub.1 is Val, J.sub.1 is Ser and K.sub.1 is Asn; then one or more of A.sub.1 to K.sub.1 is a D-amino acid and Z is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and wherein said agonist exhibits a nucleus accumbens receptor binding activity of 5 nM or less.

8. A method according to claim 7 wherein X and Y comprise Cys residues linked by a disulfide bond.

9. A method according to claim 8 wherein Z is amino.

10. The method of claim 7 wherein said amylin agonist is administered parenterally.

11. The method of claim 7 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 1 nM or less.

12. The method of claim 7 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 50 pM or less.

13. A method of reducing gastric motility or delaying gastric emptying in a mammal comprising administering to said mammal a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is an amylin agonist analogue having the following amino acid sequence: .sup.1 A.sub.1 -X-Asn-Thr-.sup.5 Ala-Thr-Y-Ala-Thr-.sup.10 Gln-Arg-Leu-B.sub.1 -Asn-.sup.15 Phe-Leu-C.sub.1 -D.sub.1 -E.sub.1 -.sup.20 F.sub.1 -G.sub.1 -Asn-H.sub.1 -Gly-.sup.25 I.sub.1 -J.sub.1 -Leu-Pro-Pro-.sup.30 Thr-K.sub.1 -Val-Gly-Ser-.sup.35 Asn-Thr-Tyr-Z

wherein A.sub.1 is Lys, Ala, Ser or hydrogen; B.sub.1 is Ala, Ser or Thr; C.sub.1 is Val, Leu or Ile; D.sub.1 is His or Arg; E.sub.1 is Ser or Thr; F.sub.1 is Ser, Thr, Gln or Asn; G.sub.1 is Asn, Gln or His; H.sub.1 is Phe, Leu or Tyr; I.sub.1 is Ala or Pro; J.sub.1 is Ile, Val, Ala or Leu; K.sub.1 is Asn, Asp or Gln; X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when A.sub.1 is Lys, B.sub.1 is Ala, C.sub.1 is Val, D.sub.1 is Arg, E.sub.1 is Ser, F.sub.1 is Ser, G.sub.1 is Asn, H.sub.1 is Leu, I.sub.1 is Pro, J.sub.1 is Val and K.sub.1 is Asn; then one or more of A.sub.1 to K.sub.1 is a D-amino acid and Z is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and wherein said agonist exhibits a nucleus accumbens receptor binding activity of 5 nM or less.

14. A method according to claim 13 wherein X and Y comprise Cys residues linked by a disulfide bond.

15. A method according to claim 14 wherein Z is amino.

16. The method of claim 13 wherein said amylin agonist is administered parenterally.

17. The method of claim 13 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 1 nM or less.

18. The method of claim 13 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 50 pM or less.

19. A method of reducing gastric motility or delaying gastric emptying in a mammal comprising administering to said mammal a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is an amylin agonist analogue having the following amino acid sequence: .sup.1 A.sub.1 -X-Asn-Thr-.sup.5 Ala-Thr-Y-Ala-Thr-.sup.10 Gln-Arg-Leu-B.sub.1 -Asn-.sup.15 Phe-Leu-C.sub.1 -D.sub.1 -E.sub.1 -.sup.20 F.sub.1 -G.sub.1 -Asn-H.sub.1 -Gly-.sup.25 Pro-I.sub.1 -Leu-Pro-Pro-.sup.30 Thr-J.sub.1 -Val-Gly-Ser-.sup.35 Asn-Thr-Tyr-Z

wherein A.sub.1 is Lys, Ala, Ser or hydrogen; B.sub.1 is Ala, Ser or Thr; C.sub.1 is Val, Leu or Ile; D.sub.1 is His or Arg; E.sub.1 is Ser or Thr; F.sub.1 is Ser, Thr, Gln or Asn; G.sub.1 is Asn, Gln or His; H.sub.1 is Phe, Leu or Tyr; I.sub.1 is lie, Val, Ala or Leu; J.sub.1 is Asn, Asp or Gln; X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when A.sub.1 is Lys, B.sub.1 is Ala, C.sub.1 is Val, D.sub.1 is Arg, E.sub.1 is Ser, F.sub.1 is Ser, G.sub.1 is Asn, H.sub.1 is Leu, I.sub.1 is Val and J.sub.1 is Asn; then one or more of A.sub.1 to K.sub.1 is a D-amino acid and Z is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and wherein said agonist exhibits a nucleus accumbens receptor binding activity of 5 nM or less.

20. The method of claim 19 wherein said amylin agonist is administered parenterally.

21. The method of claim 19 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 1 nM or less.

22. The method of claim 19 wherein said agonist exhibits a nucleus accumbens receptor binding activity of 50 pM or less.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cipla
Argus Health
UBS
AstraZeneca
Teva
Mallinckrodt
Deloitte
US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot